#KEYNOTE-689
LightNews LightNews
oncodaily.bsky.social
New Paper Alert: KEYNOTE-689. Neoadjuvant and Adjuvant Pembrolizumab Improves Survival in Locally Advanced HNC

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #KEYNOTE-689 #HNC #HNSCC
KEYNOTE-689: Pembrolizumab Boosts Survival in HNSCC
KEYNOTE-689 shows perioperative pembrolizumab significantly improves event-free survival in resectable head and neck cancer.
oncodaily.com
June 20, 2025 at 9:42 PM
oncodaily.bsky.social
From Evidence to Insight: KEYNOTE-689 Trial and Editorial on Harnessing Immunotherapy in Head and Neck Cancer
@nejm.org

oncodaily.com/science/keyn...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NEJM #KEYNOTE689 #HeadandNeckCancer
From Evidence to Insight: KEYNOTE-689 Trial and Editorial on Harnessing Immunotherapy in Head and Neck Cancer - OncoDaily
From Evidence to Insight: KEYNOTE-689 Trial and Editorial on Harnessing Immunotherapy in Head and Neck Cancer / Ari J. Rosenberg, Burak Gumuscu, cancer,
oncodaily.com
July 6, 2025 at 9:44 PM
nejm.org
For patients with locally advanced head and neck squamous-cell carcinoma, phase 2 studies indicated that adding perioperative pembrolizumab to standard care improved outcomes. Findings from KEYNOTE-689 phase 3 trial are summarized in a short video. nej.md/4kdCIml

#MedSky
An illustration of perioperative pembrolizumab plus standard care for patients with locally advanced head and neck squamous-cell carcinoma.
July 6, 2025 at 1:02 PM
ascocancer.bsky.social
Is immune priming the difference between NIVOPOSTOP and KEYNOTE 689? Or slightly higher risk population? #ASCO25
June 1, 2025 at 6:57 PM
danafarbernews.bsky.social
“It is an exciting time for patients, providers, and all who take care of patients with head and neck cancer,” Ravindra Uppaluri, MD, PhD, of the @danafarber.bsky.social Brigham Cancer Center shared with Targeted Oncology following the FDA’s approval of pembrolizumab.

Read more: bit.ly/4ldhMgo
FDA OKs Perioperative Pembrolizumab in HNSCC: Findings From KEYNOTE-689
Ravindra Uppaluri, MD, PhD, discusses findings from the KEYNOTE-689 trial in adult patients with resectable, locally advanced head and neck squamous cell carcinoma.
bit.ly
June 18, 2025 at 12:03 AM
icr.ac.uk
📰 BREAKING: Researchers show that pembrolizumab, an immunotherapy drug, helps head and neck cancer patients live years longer cancer-free. The drug also hunts down cancer trying to spread.

Results from the the phase III KEYNOTE-689 trial are presented at #ASCO25 ⤵️

www.icr.ac.uk/about-us/icr...
Professor Kevin Harrington from the ICR and The Royal Marsden, who was involved in the study, said: "This research shows that immunotherapy could change the world for these patients -- it significantly increases the chance of remaining free of disease."
May 30, 2025 at 11:43 PM
gawish.bsky.social
In the KEYNOTE-689 trial, neoadjuvant pembrolizumab delivered a game-changing:
✅ Event-Free Survival (EFS) Hazard Ratio: 0.73 (95% CI: 0.58–0.92)
✅ Median EFS: 51.8 months vs. 30.4 months
No clear benefit seen in the hypopharynx subgroup
#HNSCC #Radonc #Immunotherapy #CancerResearch
April 28, 2025 at 3:47 AM
nejm.org
In the KEYNOTE-689 phase 3 trial, the addition of neoadjuvant and adjuvant pembrolizumab to standard care improved event-free survival among participants with locally advanced head and neck cancer without affecting surgical outcomes. Full trial results: nej.md/45X0Nuc

#MedSky #Oncology
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer | NEJM
The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unc...
nej.md
June 18, 2025 at 9:01 PM
oncodaily.bsky.social
Practice-Changing Data in Head and Neck Cancer - Yan Leyfman
@yleyfman.bsky.social

oncodaily.com/science/yan-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #HNC #HNSCC #HeadandNeckCancer #KEYNOTE-689 #Pembrolizumab
Yan Leyfman: Practice-Changing Data in Head and Neck Cancer - OncoDaily
Yan Leyfman: Practice-Changing Data in Head and Neck Cancer / cancer, Head and Neck Cancer, HNSCC, immunotherapy, OncoDaily, Oncology, pembrolizumab, Yan
oncodaily.com
June 21, 2025 at 9:23 PM
ascopost.bsky.social
Interim results from KEYNOTE-689 (NEJM): Perioperative pembrolizumab + standard care improved 3-yr EFS in locally advanced HNSCC (CPS ≥10: 59.8% vs 45.9%). Led by
@druppaluri.bsky.social

Details: ascopost.com/news/june-20...

#KEYNOTE689 #HNSCC #Oncology
June 30, 2025 at 5:57 PM
cancergrace.bsky.social
Keynote 689 Pembrolizumab for Locally Advanced Disease 2025 Head and Neck Advances youtu.be/uFMF0FRfKYU?... via @YouTube

In this video, the panel discusses the findings of the Keynote 689 study, which showed improved EFS in patients with head and neck cancers treated with pembrolizumab.
Keynote 689 Pembrolizumab for Locally Advanced Disease 2025 Head and Neck Advances
YouTube video by GRACE - Global Resource for Advancing Cancer Education
youtu.be
June 17, 2025 at 8:59 PM
handle.invalid
KEYNOTE-689 en #AACR25: 🛡️ Agregar #inmunoterapia antes y después de la cirugía mejoró significativamente la supervivencia libre de eventos ⏳ en pacientes con cáncer de cabeza y cuello resecable. 🔥 Mayor tasa de respuesta patológica mayor. 📈 Tendencia ➕ en supervivencia global. 🚀 #HNSCC
April 27, 2025 at 10:02 PM
nejm.org
In the KEYNOTE-689 phase 3 trial, the addition of neoadjuvant and adjuvant pembrolizumab to standard care improved event-free survival among participants with locally advanced head and neck cancer without affecting surgical outcomes. Full trial results and Research Summary: nej.md/45X0Nuc
The New England Journal of Medicine Pembrolizumab in Locally Advanced Head and Neck Cancer A Research Summary based on Uppaluri R et al. | 10.1056/NEJMoa2415434 | Published on June 18, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
July 9, 2025 at 1:03 PM
cpickering.bsky.social
This week I want to share the new review article from @druppaluri.bsky.social about neoadjuvant immunotherapy in HNSCC. This review is a comprehensive summary of the field as we wait for the results of KEYNOTE-689.
www.nature.com/articles/s41...
T cell dynamics with neoadjuvant immunotherapy in head and neck cancer - Nature Reviews Clinical Oncology
Neoadjuvant administration of immune-checkpoint inhibitors (ICIs) has substantially improved the outcomes in patients with various solid tumours, including those with head and neck cancer. However, no...
www.nature.com
December 11, 2024 at 9:28 PM
vhio.bsky.social
🗞️ Published in @nejm.org, results from KEYNOTE-689 clinical trial show that the addition of immunotherapy before and after surgery improves outcomes in patients with locally advanced head and neck cancer. 

👉 https://linke.to/KEYNOTE-689VHIO
June 27, 2025 at 4:22 PM
cyrilpedia.bsky.social
"This phase 3, open-label, randomized trial (KEYNOTE-689) investigated the efficacy & safety of neoadjuvant and adjuvant pembrolizumab plus standard care as compared with standard care alone in patients with resectable locally advanced HNSCC."
#Immunotherapy #Immunology
www.nejm.org/doi/full/10....
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer | NEJM
The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unc...
www.nejm.org
June 26, 2025 at 5:54 AM
ascopost.bsky.social
⭐️ KEYNOTE-689 trial
Pembrolizumab + surgery & adjuvant chemoradiotherapy for #HeadAndNeckCancer
✔️ Improved event-free & distant metastasis-free survival
🔬 Douglas Adkins, MD; Kevin Harrington, MBBS, PhD
Expert insights included👇
🔗 ascopost.com/news/july-20...
August 5, 2025 at 4:44 PM
ascopost.bsky.social
FDA approves pembrolizumab for resectable, locally advanced HNSCC based on KEYNOTE‑689. Led by Dr. Ravindra Uppaluri, the study showed a 30% drop in recurrence risk. Full details from The ASCO Post: ascopost.com/news/june-20... #HNSCC #Oncology
June 16, 2025 at 3:05 PM
icr.ac.uk
Today is World Head and Neck Cancer Day

Research from the ICR has shown that pembrolizumab, an immunotherapy drug, helps head and neck cancer patients live years longer cancer-free.

Read about the results from the phase III KEYNOTE-689 trial ⬇️

www.icr.ac.uk/about-us/icr...
July 27, 2025 at 10:57 AM
handle.invalid
KEYNOTE-689 at #AACR25: 🛡️ Adding #immunotherapy before and after surgery significantly improved event-free survival ⏳ in patients with resectable head and neck cancer. 🔥 Higher major pathological response rates. 📈 Early trend toward improved overall survival. 🚀 #HNSCC #CancerResearch
April 27, 2025 at 9:57 PM
danafarbernews.bsky.social
Adding perioperative pembrolizumab to standard of care is “a new frontier” for head and neck cancer, @danafarber.bsky.social’s Ravindra Uppaluri, MD, PhD, tells @gohealio.bsky.social. bit.ly/435ercJ
Perioperative immunotherapy ‘a new frontier’ for head, neck cancer
The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain patients with advanced head and neck squamous cell carcinoma, according to results of a randomized phase 3 study.Findings from the KEYNOTE-689 trial, presented at American Association for Cancer Research Annual Meeting, showed individuals with stage III or IVA resected, locally
bit.ly
April 29, 2025 at 6:16 PM
uchicagocancer.bsky.social
In a recently published article in NEJM, Ari Rosenberg, MD, and Everett Vokes, MD, discuss the promise and complexities of the KEYNOTE-689 trial, which shows event-free survival benefits from pembrolizumab in curative-intent settings. @arirosenbergmd.bsky.social
pubmed.ncbi.nlm.nih.gov/40532147/
Harnessing Immunotherapy in Curative-Intent Treatment of Head and Neck Cancer - PubMed
Harnessing Immunotherapy in Curative-Intent Treatment of Head and Neck Cancer
pubmed.ncbi.nlm.nih.gov
June 27, 2025 at 5:33 PM
chaewonhwangmd.bsky.social
📣 Phase III KEYNOTE-689 trial: Addition of perioperative Pembrolizumab to standard of care tx for locally advanced HNSCC significantly improved event free survival and major pathologic response. Presented
@ #AACR 2025 meeting: www.aacr.org/about-the-aa...

#Oncology #research #radonc
About the AACR
The American Association for Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the conquest of cancer.
www.aacr.org
April 28, 2025 at 1:57 AM
icr.ac.uk
The phase III KEYNOTE-689 trial was led by Washington University School of Medicine, USA and funded by MSD.

Read about the results of the trial, presented at the @theaacr.bsky.social annual meeting ⬇️
Immunotherapy gives head and neck cancer patients extra years disease free
An immunotherapy treatment helps patients live years longer without their cancer getting worse or coming back, a major phase III trial has found.
www.icr.ac.uk
April 29, 2025 at 2:04 PM
ascopost.bsky.social
Perioperative pembrolizumab added to standard therapy in newly diagnosed, locally advanced head and neck cancer: findings suggest potential implications for practice. Details on trial design and outcomes: ascopost.com/issues/may-1...
#Immunotherapy #HeadNeckCancer
Addition of Perioperative Pembrolizumab to Standard of Care in Newly Diagnosed Locally Advanced Head and Neck Cancer
In the phase III KEYNOTE-689 trial, perioperative use of a PD-1 inhibitor given with standard therapy significantly improved event-free survival in newly diagnosed, previously untreated patients with ...
ascopost.com
May 12, 2025 at 5:46 PM